Supernus Pharmaceuticals SUPN Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues by Product | |||||
| APOKYN | $47.77M-35.4% | $73.93M-1.5% | $75.08M-0.3% | $75.31M-24.1% | |
| Collaboration revenue (ZURZUVAE) | $53M— | —— | $0— | —— | |
| GOCOVRI | $146.82M+12.2% | $130.82M+9.4% | $119.64M+14.6% | $104.42M+968% | |
| ONAPGO | $17.25M— | $0— | $0— | —— | |
| Other | $26.91M-7.2% | $29.01M-7.3% | $31.28M-1.7% | $31.82M-3.8% | |
| Oxtellar XR | $40.7M-59.1% | $99.46M-12.3% | $113.4M-1.7% | $115.35M+4.2% | |
| Qelbree | $304.65M+26.3% | $241.27M+72.1% | $140.19M+129% | $61.32M+521% | |
| Royalty, licensing, and other revenues | $39.42M+63.4% | $24.12M-28.2% | $33.59M+88.6% | $17.81M— | |
| Trokendi XR | $42.42M-32.9% | $63.2M-33.0% | $94.34M-63.9% | $261.22M-14.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Supernus Pharmaceuticals break its business down?
- Supernus Pharmaceuticals (SUPN) reports total revenues by product across 9 parts — APOKYN, Collaboration revenue (ZURZUVAE), GOCOVRI, ONAPGO and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Supernus Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Supernus Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.